Enzalutamide Monotherapy for the Treatment of Prostate Cancer With High-Risk Biochemical Recurrence: EMBARK Secondary Endpoints

Key Points

• The treatment with enzalutamide led to improved outcomes for patients with prostate cancer and biochemical recurrence.
• Key evidence indicates a significant improvement in progression-free survival rates in patients receiving enzalutamide therapy.
• This study employs observational analysis to evaluate the efficacy of enzalutamide in treating high-risk prostate cancer.
• The findings suggest that enzalutamide could be a valuable option, but further studies in larger populations are needed.